key: cord-0754150-hwzue1tx
authors: Sen, Sanjana R.; Sanders, Emily C.; Santos, Alicia M.; Bhuvan, Keertna; Tang, Derek Y.; Gelston, Aidan A.; Miller, Brian M.; Ricks-Oddie, Joni L.; Weiss, Gregory A.
title: Evidence for Deleterious Original Antigenic Sin in SARS-CoV-2 Immune Response
date: 2021-05-24
journal: bioRxiv
DOI: 10.1101/2021.05.21.445201
sha: d4a49b5bceb6032a36faed938b9703d81f358355
doc_id: 754150
cord_uid: hwzue1tx

A previous report demonstrated the strong association between the presence of antibodies binding to an epitope region from SARS-CoV-2 nucleocapsid, termed Ep9, and COVID-19 disease severity. Patients with anti-Ep9 antibodies (Abs) had hallmarks of original antigenic sin (OAS), including early IgG upregulation and cytokine-associated injury. Thus, the immunological memory of a previous infection was hypothesized to drive formation of suboptimal anti-Ep9 Abs in severe COVID-19 infections. This study identifies a putative original antigen capable of stimulating production of cross-reactive, anti-Ep9 Abs. From bioinformatics analysis, 21 potential “original” epitope regions were identified. Binding assays with patient blood samples directly show cross-reactivity between Abs binding to Ep9 and only one homologous potential antigen, a sequence derived from the neuraminidase protein of H3N2 Influenza A virus. This cross-reactive binding affinity is highly virus strain specific and sensitive to even single amino acid changes in epitope sequence. The neuraminidase protein is not present in the influenza vaccine, and the anti-Ep9 Abs likely resulted from the widespread influenza infection in 2014. Therefore, OAS from a previous infection could underlie some cases of COVID-19 disease severity and explain the diversity observed in disease outcomes.

Original antigenic sin (OAS) occurs when the immune responses adapted for a primary 66 (or "original") infection instead target a similar, but not identical, pathogen (Fierz & Walz, 2020) . 67

Since B-cells undergo affinity maturation post-primary infection, affinity-matured Abs from 68 previous infections can sometimes outcompete naïve Abs with specificity for the new antigen 69 (Brown & Essigmann, 2021) . The phenomenon has been observed for immune responses to 70 dengue fever, influenza, respiratory syncytial virus and human immunodeficiency virus (HIV) 71 (Park, Kim, Park, Lee, & Park, 2016; Welsh & Fujinami, 2007) . OAS ideally accelerates pathogen 72 clearance by targeting highly conserved antigens; however, suboptimal targeting by non-73

neutralizing Abs binding to the antigen can exacerbate disease conditions by either enhancing 74 viral infection or hyperactivating the innate immune response (Brown & Essigmann, 2021) . The 75 wide range of outcomes observed in SARS-CoV-2 infected individuals, from asymptomatic to 76 fatal, has been hypothesized to result from a patient's unique immunological memory (Fierz & 77 Walz, 2020; Kohler & Nara, 2020) . 78

Reports of OAS in COVID-19 patient have largely focused on the phenomenon's beneficial 79 or benign impacts on the immune response. For example, Abs from individuals naïve for SARS-80

CoV-2 infection, but exposed to other common human coronaviruses (hCoV), could cross-react 81 with SARS-CoV-2 spike protein and neutralize SARS-CoV-2 pseudotypes (Ng et al., 2020) . 82

Plasma collected before the pandemic had Abs cross-reactive with SARS-CoV-2 nucleocapsid 83 (NP) and spike proteins; these Abs did not confer protection against severe COVID-19 outcomes 84 (Anderson et al., 2020) . Though higher rates of prior cytomegalovirus and herpes simplex virus 1 85 infections have been reported for hospitalized COVID-19 patients versus patients with milder 86 symptoms, no Ab signature linked to a molecular mechanism has been shown (Shrock et al., 87 2020) . Humoral immunity to hCoVs, NL63 and 229E, has been associated with more severe 88 COVID-19 disease (Focosi et al., 2021) . 89 CoV-2 to the bioinformatics-identified, closest homologs. Sequence alignments used pBLAST 142

and VAST, and the cladogram was generated by iTOL (Letunic & Bork, 2019 The strain specificity of αEp9 Abs binding to H3N2 influenza A NA protein was tested next. 164

The EpNeu sequence provided the template for pBLAST homolog searching. Closely aligned NA 165 sequences isolated from human, avian, and swine hosts in North America were chosen for further 166 analysis ( Figure 1F , Figure 1 -supplement 1). The six sequences were phage-displayed as before. 167

Despite their close similarity to EpNeu (up to 92.3% similarity or only one residue difference), 168 none of the EpNeu homologs bound to Abs from αEp9(+) patients ( Figure 1E ). A single EpNeu 169 amino acid substitution, K142N (numbering from full-length NA, Accession No. AID57909.1) 170 occurs in an H1N2 swine flu from 2016; the single substitution dramatically decreased binding 171 affinity to Abs from αEp9(+) patients (p<0.0001 one-way ANOVA ad hoc Tukey). The epitope from 172 H4N6 avian influenza A from 2010 omits residue S141, but includes the conserved K142, also 173 greatly reduced binding to Abs from αEp9(+) patients (p<0.0001 one-way ANOVA ad hoc Tukey) 174 ( Figure 1E , F). Therefore, S141 and K142 are critical for binding to αEp9 Abs. Next, ELISAs were used to determine whether Ep9 and EpNeu epitopes bind to the same 195

Abs. Assays of 34 αEp9(+) patients demonstrated a strong and highly significant correlation 196 between levels of Abs binding to Ep9 and EpNeu epitopes in patient plasma, suggesting the two 197 epitopes may bind to the same Abs ( Figure 2C ). This cross-reactivity was confirmed by a 198 sandwich-format assay requiring bivalent, simultaneous binding by Abs to Ep9 and EpNeu ( Figure  199 2D, Figure 2 -supplement 1). In this assay, Ep9 was fused to the N-terminus of eGFP, and EpNeu 200 was phage-displayed. The results demonstrated binding of Abs to both Ep9 and EpNeu epitopes 201 in pooled plasma from αEp9(+) patients, but not in αEp9(-) patients with other αNP Abs or healthy 202 donors. Thus, we conclude that αEp9 Abs also recognize the EpNeu epitope region. 203 blue) with an additional ten, C-terminal residues (dark blue This report offers a molecular mechanism for OAS underlying the high-rate of severe 259 COVID-19 in αEp9(+) patients. Specifically, we demonstrate cross-reactive binding between 260 αEp9 Abs and a predicted NA epitope from a 2014 influenza A strain. Interestingly, a study of an 261

Italian patient cohort correlated COVID-19 disease outcomes with previous RSV and 262

herpesviruses, but not influenza A infections (Wang et al., 2020) . Future studies could examine 263 correlation between a country's rate of the H3N2 2014 influenza and severe COVID-19. 264

Additionally, health systems might have recorded such primary infections in specific patients, 265 which could also be searched for correlation. Examining epitope conservation and Ab cross-266 reactivity could predict OAS-based immune responses and disease outcomes in future infections. 267

Identifying detrimental, benign or beneficial OAS pathways could also guide vaccine design for 268 increased efficacy and reduced risk. EpNeu and EpPred or eGFP-FLAG, and incubated overnight at 4 °C before blocking as described 423

above. Next, pooled plasma (100 µl per well) from either five αEp9(+) patients, or five αEp9(-) 424 patients, or healthy individuals at 1:100 total plasma dilution in CBB was added to the appropriate 425 wells. Samples were incubated for 1 h at RT with shaking at 150 rpm. After incubation, unbound 426 solution was removed, and the plates were washed three times with PBS-T. αEp9 IgG levels were 427 detected by adding αFc IgG-HRP diluted 1:5000 in ChonBlock Sample Dilution buffer, followed 428 by incubation for 30 min at RT with shaking at 150 rpm, followed by addition of TMB substrate 429 (100 µl per well). Experiments were conducted in technical triplicates and repeated three times scores were calculated to predict likely B-cell epitope residues. The score of -3.7 was set as the 452 threshold for epitope prediction, which estimates a specificity and sensitivity of 0.75 and 0.47, 453 respectively ( Figure 3 -supplement 1) . 454 455

The ELISA data were analyzed in GraphPad Prism 9 (https://www.graphpad.com). Since 457 the ELISA assays of 21 potential OAS epitopes were conducted over several microtiter plates for 458 repeated experiments, the raw absorbance values for every patient sample were normalized and 459

represented as the ratio of phage negative control to the signal. For heatmaps, two-way Analysis 460 of variance (ANOVA) with a Tukey adjustment for multiple comparisons tests were conducted for 461 the entire dataset of epitopes. For column comparisons of two groups, for example IgM levels and 462

IgG levels in the αEp(+) patients, unpaired, two-tailed, parametric t-tests were applied. 463

Additionally, for column comparisons between more than two groups, for example IgM or IgG 464 levels groups by weeks PSO, One-way ANOVA with a Tukey adjustment for multiple comparisons 465 tests were used. Where indicated, an ANOVA with a Dunnett's adjustment were performed to 466 compare results to healthy Abs interactions to αEp9(+) patient results. Optimization of assay to determine cross-reactivity of αEp9 Ab to Ep9 and EpNeu. 

Gapped BLAST and PSI-BLAST: A new generation of protein database 532 search programs

Seasonal human coronavirus antibodies 535 are boosted upon SARS-CoV-2 infection but not associated with protection

Benchling

Modeling protein 539 quaternary structure of homo-and hetero-oligomers beyond binary interactions by 540 homology

The SWISS-MODEL Repository-new features and functionality

Original Antigenic Sin: the Downside of 545

Immunological Memory and Implications for COVID-19

Antibody Dependent Enhancement Due to Original Antigenic 548 Sin and the Development of SARS

Enhanced Genetic Characterization of Influenza A(H3N2)

Journal of 553 Infectious Diseases

Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses 557 NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and 558

Suggests Original Antigenic Sin

Antibody 560 neutralization of an influenza virus that uses neuraminidase for receptor binding

Automated comparative protein structure 563 modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective

BepiPred-2.0: Improving 566 sequence-based B-cell epitope prediction using conformational epitopes

A Novel Hypothesis for Original Antigenic Sin in 569 the Severe Disease of SARS-CoV-2 Infection. Monoclonal Antibodies in 570 Immunodiagnosis and Immunotherapy

Interactive Tree of Life (iTOL) v4: Recent updates and new 576 developments

Exploring the interaction between the protein kinase A catalytic 579 subunit and caveolin-1 scaffolding domain with shotgun scanning, oligomer 580 complementation, NMR, and docking

Purification of viral neuraminidase from inclusion bodies produced by recombinant 584 Escherichia coli

MMDB and VAST+: Tracking structural similarities between 588 macromolecular complexes

Statistics corner: A guide to appropriate use of correlation 591 coefficient in medical research

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Original antigenic sin 596 response to RNA viruses and antiviral immunity. Immune Network. Korean 597 Association of Immunologists

Heat 599 inactivation of different types of SARS-CoV-2 samples: What protocols for biosafety, 600 molecular detection and serological diagnostics?

Predicting COVID-19 Severity with a Specific Nucleocapsid 604

Antibody plus Disease Risk Factor Score

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and 608 correlates of severity

QMEANDisCo-distance constraints applied on model quality estimation

ProMod3 -A versatile homology modelling toolbox

Serological responses to human virome define clinical outcomes of italian patients 617 infected with SARS-CoV-2

Pathogenic epitopes, heterologous immunity and 622 vaccine design

WHO | Cumulative Number of Reported Probable 625 Cases of Severe Acute Respiratory Syndrome (SARS)

Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head 629